This is a multicenter, prospective, double blinded, randomized, two-arm phase II trial aiming to evaluate nintedanib treatment as switch maintenance in patients with unresectable MPM.~After signing of the informed consent and upon confirmation of all eligibility criteria, patients will be randomized 1:1 to:~Arm A: twice daily nintedanib at a dose of 200 mg until progression or unacceptable toxicities.~Arm B: matched placebo.~Response evaluation will be performed through CT scans every 8 weeks.
This is a multicenter, randomized, 1:1, double blinded phase II trial. Patients with unresectable malignant pleural mesothelioma (MPM) will be randomized between arm A: nintedanib and arm B:placebo